

Title

Progress in defining the biological causes of schizophrenia

Author contact details

Benjamin Pickard, Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK
Tel: +44 (0)141 548 4572, FAX: +44 (0)141 552 2562
Email:benjamin.pickard@strath.ac.uk

Abstract

Schizophrenia is a common mental illness resulting from a complex interplay of genetic and environmental risk factors. Establishing its primary molecular and cellular aetiopathologies has proved difficult. However, this is a vital step towards the rational development of useful disease biomarkers and new therapeutic strategies.

The advent and large-scale application of genomics, transcriptomics, proteomics and metabolomics technologies is generating datasets required to achieve this goal. This discovery phase, typified by its objective and hypothesis-free approach, is described in the first part of the review. The accumulating biological information, when viewed as a whole, reveals a number of biological process and subcellular locations that contribute to schizophrenia causation. The data also show that each technique targets different aspects of central nervous system function in the disease state.

In the second part of the review, key schizophrenia candidate genes are discussed more fully. Two higher order processes, adult neurogenesis and inflammation, that appear to have pathological relevance, are also described in detail.

Finally, the review discusses three areas where progress would have a large impact on schizophrenia biology: deducing the causes of schizophrenia in the individual, explaining the phenomenon of cross-disorder risk-factors, and distinguishing causative disease factors from those that are reactive or compensatory.

Keywords

Schizophrenia, bipolar disorder, neurogenesis, dopamine hypothesis, glutamate hypothesis, inflammation, neurodevelopmental hypothesis, genome-wide association, copy number variation, proteomics, transcriptomics, metabolomics, next generation sequencing, transgenic models, cytoskeleton, metabolism, mitochondria

“One may speculate about some far future in which individuals will routinely undergo ‘genic analysis’, as nowadays they are routinely vaccinated....Perhaps massive genic analysis of the population will eventually give us the information that will lead to working out the physical basis for mental disease.”

Isaac Asimov

The Genetic Code (1962)

Publ. The New American Library, Inc.

Introduction

Schizophrenia is a chronic and severe mental illness defined by the presence of delusions and hallucinations (positive symptoms), apathy and social withdrawal (negative symptoms), and specific cognitive failures (Ref. 1). It is diagnosed through qualitative assessment of patient interview and case notes with reference to an agreed set of classification criteria. The absence of objective biological tests for schizophrenia (for example, through blood sample analysis or physiological readout) are a hindrance to disease prediction, diagnosis, therapeutic assessment and scientific research. The intangibility of the diagnosis results from the difficulties in assessing the living brain in conjunction with the substantial heterogeneities in biological origin and clinical presentation of the disorder.

In this regard, a detailed description of the biology of schizophrenia would be invaluable. Traditionally, such a description has been based on three principal observations. Firstly, there is the pharmacologically defined involvement of specific neurotransmitter receptor systems and their particular anatomical pathways in the brain. The action of amphetamine in inducing or worsening psychotic symptoms suggested that dopaminergic hyperactivity is an important component of illness. Further elucidation of the key dopaminergic tracts in the brain affected by receptor-blocking antipsychotic medication explained both the alleviation of positive symptoms as well as motor-control side-effects. Hypofunction of the glutamatergic neurotransmitter system is also implicated through the action of neurotransmitter receptor antagonists such as PCP and ketamine, together with expression studies that show reduced subunit expression in post mortem brain samples from individuals diagnosed with schizophrenia (Ref. 2). Secondly, evidence from brain imaging approaches has provided evidence for regional brain abnormalities in structure – implicating neurodevelopment – and function associated with illness. Some of these features correlate with genetic risk status, as recently reviewed (Ref. 3). Thirdly, particular cellular pathologies in have been described in brains from patients diagnosed with schizophrenia: for example, reduced oligodendrocyte number

(Ref. 4) or altered neuronal cytoarchitecture (Ref. 5). Until recently, these ‘high-level’ observations, while highly informative, have not been matched by an understanding of the underlying genetic and molecular mechanisms.

Schizophrenia is partly genetic (Ref. 6, 7, 8, 9) although its ‘genetic architecture’ (how many and what type of mutations contribute to illness in the individual and population) is still a subject of much debate (Ref. 10). The existence of families with a high density of affected individuals suggests that segregating unitary gene effects can strongly predispose to illness. However, not all diagnosed individuals show such inheritance patterns indicating that common, small-effect variants in multiple genes, co-occurring through random and transitory co-segregation, are able to produce a form of the disorder phenotypically indistinguishable from the familial. Evidence from epidemiology (Ref. 11) and the genomic studies described below suggests that certain genes are risk factors not only for schizophrenia, but also for bipolar disorder (Ref. 12, 13) and major depression (Ref. 14), hinting at a degree of biological overlap.

In the eight years since the genetics of schizophrenia were last reviewed in this journal (Ref. 15), research in the field has been transformed in direction and ambition by the advent of ‘whole genome’ technologies, revealing the common genetic variation and rare DNA copy number variants (CNVs) that contribute to risk of illness. In parallel, the use of structural and functional brain imaging, bio-marker discovery through transcriptomics and proteomics, and the generation of several mouse disease models, is increasing our understanding of how primary biological deficits are translated into clinical outcome (Ref. 16, 17, 18, 19, 20, 21). This review sets out the major discoveries from such studies – primarily those at the molecular and cellular end of brain functional hierarchy. While a broad but shallow approach is inevitable, there is a clear intention to highlight findings spanning research strategies and to discuss those techniques that perhaps do not currently receive the attention that they merit. With that in mind, the review covers paths to discovery, notable gene candidates, emerging processes, and ends with a discussion of three issues facing the field of schizophrenia research. Key reviews have been signposted throughout to allow the reader to explore specific aspects in more detail.

The discovery process

Genome-wide association studies

The genetic information responsible for the development and regulation of the brain is the foundation of its functional operation. This position suggests that genetic studies are the most likely to reveal primary and causative factors predisposing to illness. Case-control association studies reveal the contribution of common genetic variation to risk of disease. The last 5 years have seen impressive progress following the move away from small, gene-specific studies towards the large genome-wide association studies (GWAS). These have been made possible by the sharing of DNA samples within consortia and the technological advances in the massively parallel detection of single nucleotide polymorphisms (SNPs) that make up the greater part of common variation. The GWAS experimental design makes no subjective assumptions concerning gene candidacy or even genic contribution (the studies include SNPs in gene-poor regions of the genome). This feature – along with the cytogenetic approaches detailed below - will probably do most to benefit the biological understanding of schizophrenia as it has bypassed the subjective and cyclical knowledge that drove much earlier individual genetic and biological studies. Numerous individual studies and some combined meta-analyses (Ref. 22, 23, 24, 25, 26, 27, 28, 29, 30) have been carried out for schizophrenia – the latter intended to boost signal-to-noise ratio resulting from locus and allelic heterogeneity. A current estimate places the genetic contribution of common polymorphic variation to risk of schizophrenia at ~34% (Ref. 25).

Identified genes have been subjected to specific replication studies as well as examination in related conditions such as bipolar disorder and major depression. The major confirmed finding is the association of schizophrenia with a broad swathe of markers on chromosome 6p22.1 (Ref. 25, 26, 27). This locus houses the Major Histocompatibility Complex (MHC) consisting, in part, of the Human Leukocyte Antigen (HLA) genes that mediate the body's monitoring of self and non-self in the context of infection. The potential role of the immune system in psychiatric disorder aetiology makes this an important finding and is discussed in more detail later. However, a note of caution must be attached to the finding. The MHC region is highly mutable, subject to strong natural selection, and known to influence mammalian mate choice. These are features all known to perturb the Hardy-Weinberg Equilibrium of allele frequencies in populations. Careful analysis will be required to ensure that the GWAS signals detected here are specifically attributable to influence on schizophrenia risk. Aside from the MHC genes, the associated region also contains a number of other genes including *NOTCH4*, a previously identified candidate gene with a neurodevelopmental role (Ref. 31), and a

histone gene cluster. We have recently shown that the histone cluster is co-ordinately regulated by the transcription factor SOX11 responsible for neuronal differentiation (Ref. 32) suggesting that chromatin modification might be an alternative biological explanation for the association.

Aside from the MHC region, GWAS studies have highlighted variants strongly linked with risk of schizophrenia within the following individual genes: *ZNF804A*, *MYO18B/ADRBK2*, *AGAP1 (CENTG2)*, *NTRK3*, *EML5*, *ERBB4*, *NRGN*, *TCF4*, *CCDC60*, *RBP1*, *PTPN21*, *CMYA5*, *PLAA*, *ACSM1*, *ANK3*, *SULT6B1*, *ASTN1*, *CNTNAP1*, and *GABRR1*. Using an additional criterion of independent identification in at least two studies (including those also targeting bipolar disorder (Ref. 12)), the following genes may also be associated: *ASTN2*, *OPCML*, *PSD3*, *RYR3*, *TMCC2*, *GRID1*, *A2BP1*, *CACNA1C*, *CNTN5*, *CRYBB1*, *EML5*, *CSMD1*, *FAM69A*, *LRP8*, *PTPRG1*, *SLIT3*, *TMEM17*, and *VGCNL1/NALCN*. As further GWAS studies and meta-analyses amass (including those from non-Northern European populations) and cross-diagnostic comparisons are made, this list will slowly evolve into a robust set of candidates. A range of statistical methodologies and gene categorisation resources are now being leveraged to translate GWAS data into associated gene functions in order to define key biological processes perturbed in schizophrenia (Ref. 33). One study of gene functions enriched in single schizophrenia GWAS identified glutamate metabolism, apoptosis, and inflammation/immunity as major processes (Ref. 34). Another report found significant over-representation of cell adhesion molecules in two schizophrenia GWAS studies and moderate evidence in support of tight junction, cell cycle, glycan synthesis and vesicle transport pathways (Ref. 35).

The extraction of biological pathway information from GWAS data will always be tempered by the fact that common variant frequencies have been modulated by ancient founder effects, selection pressures, and the migratory history of human populations. These geographical and pathological filters may limit the ability of GWAS to signpost the full range of genes and processes that underlie schizophrenia.

Copy number variation and other cytogenetic failings

Deviations from diploid copy number in the genome have been long recognised – particularly in the context of the duplications and deletions observed in cancer – but the full extent of copy number variants (CNVs) in humans has only been appreciated relatively recently (Ref. 36, 37, 38). In contrast to common SNPs, common CNVs do not

seem to predispose to disease risk (Ref. 39). Therefore the focus has been to identify rare CNVs enriched in, or specific to, schizophrenia (Ref. 40, 41, 42). As a consequence, the chief issue has therefore been how to statistically prove a causative role to a given rare CNV in a numerically limited sample set. Five properties of the CNVs discovered in schizophrenia are important to highlight. Firstly, CNVs appear largely randomly throughout the genome. They can be sporadic (clearly observed in autism) or (perhaps subsequently) present as familial forms. Hence, compared to common SNPs, CNVs may define a broader gene contribution to illness given sufficient sample size. Secondly, both deletions and duplications have been observed at specific loci in schizophrenia. This implies that copy number deviation, rather than direction of change, is the chief mediator of disease – a finding that holds true for other disorders and testifies to the subtleties of evolved gene expression regulation (Ref. 43). Thirdly, several very large CNVs that simultaneously alter the dosage of multiple genes, including those found at 1q21.1, 2q12, 3q29, 7q36.3, 15q13.3, 16p11.2 16p13.1, 17q12, and 22q11.2, are repeatedly and consistently over-represented in schizophrenia (Ref. 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54). Among these, the 22q11.2 CNV represents a sub-microscopic version of the previously described chromosome 22 deletion that underlies velo-cardio-facial syndrome (VCFS)/DiGeorge syndrome - the most common genetically-defined risk factor for schizophrenia. A considerable challenge will be to dissect these 'syndromic' CNVs and expose the relative contribution of each constituent gene to the final clinical diagnosis. Fourthly, certain CNVs (particularly larger ones) initially linked to schizophrenia also contribute to the risk of other diagnoses such as autism spectrum disorder, developmental delay, mental retardation and epilepsy. The most convincing explanation for this observation is that these CNVs perturb brain development; an effect that is compounded by other gene variants (as a 'second hit' (Ref. 55)) or by the environment to define the precise clinical endpoint. The earlier observation of increased frequency and heritability of schizophrenia in individuals diagnosed with mental retardation can also be explained by the same neurodevelopmental model (Ref. 56). Finally, the degree to which CNVs contribute to the general risk of bipolar disorder is still uncertain (Ref. 39, 57, 58), but appears less than for schizophrenia. However, CNVs are associated with early-onset bipolar disorder supporting the notion that CNVs are strongly linked to the kind of neurodevelopmental dysfunction that may be a distinguishing feature of schizophrenia.

Small CNVs present an opportunity to identify individual candidate genes. The following is a non-exhaustive list of genes occurring in at least two schizophrenia CNV studies: *A2BP1*, *ACP6*, *BCL9*, *CHD1L*, *CHRNA7*, *CLDN5*, *CNTNAP2*, *DLG2*, *FHIT*, *FLJ39739*, *FMO5*, *GJA5*, *GJA8*, *GNB1L*, *KLF13*, *NRXN1*, *PARK2*, *PRKAB2*, *TRPM1* and *VIPR2*. Additionally, the following genes show overlap between schizophrenia and bipolar disorder CNV studies: *GRM7*, *LARGE*, *PTPRD*, *RTN4R*, *SNAP29*, *SOX5*, *TXNIP*, *UFD1L*, and *ZNF74*. Generally, genes within CNVs associated with schizophrenia are statistically over-represented with functions relating to neurodevelopment, synaptic transmission, and signal transduction.

An older form of cytogenetic investigation based on microscopic study of patient chromosome rearrangements has been productive in the search for schizophrenia risk genes in individuals and families (Ref. 59). Chromosomal disruption can sometimes be localised within specific genes that immediately become strong candidates for disease causation. A notable example is the study of a t(1;11) translocation disrupting the *DISC1* (disrupted in schizophrenia) gene in a Scottish family (Ref. 60, 61, 62, 63). Importantly, the large family size not only allowed the translocation to be statistically linked with illness but also allowed the detailed phenotypic assessment of family members – including the observation that diagnosis-free obligate carriers of the translocation nevertheless possessed measurable deficits in cognitive endophenotypes (Ref. 64, 65). It can be speculated that in these individuals the primary neurodevelopmental deficit is quantifiable but has not been matched by additional genetic or environmental factors required to cross a threshold into illness. Another gene, *PDE4B*, disrupted in an independent translocation event associated with schizophrenia, encodes a phosphodiesterase enzyme subsequently shown to bind to *DISC1*, thus providing a good example of functional convergence (Ref. 66).

Other candidate schizophrenia genes identified via the cytogenetic route include a glutamate metabolism pathway enzyme, *PSAT1* (Ref. 67), a kainate type ionotropic glutamate receptor, *GRIK4/KA1* (Ref. 68, 69, 70), a member of the ATP-binding cassette membrane transporter family, *ABCA13*, (see section of rare variants below and (Ref. 71)) and a brain transcription factor, *NPAS3* (Ref. 72, 73, 74). The last of these has also been identified as a moderately significant risk factor for schizophrenia, bipolar disorder and major depression through GWAS analysis (Ref. 14, 75).

Rare gene sequence variants in schizophrenia

The field awaits data from the final stage in genome-wide data gathering – the high throughput sequencing methodologies targeting rare variants in individual patients. A recent study has suggested that rare sequence variants are likely to contain a disproportionate number of non-synonymous pathological changes – a consequence of continuing negative selection pressure in the population (Ref. 76). However, the observation that the sequenced exomes of nominally healthy individuals reported to date all show multiple rare and apparently disruptive coding variants strongly predicted to cause illness is an indication that caution is warranted (Ref. 77). This reduced penetrance/compensation is likely to make rare variant confirmation statistically challenging. To date the analysis of rare variants associated with schizophrenia has largely been carried out on a gene-by-gene basis with conventional sequencing methodology. *DISC1* (Ref. 78), *ABCA13* (Ref. 71), *KIF17* (Ref. 79), and *PCM1* (Ref. 80) are examples of candidate genes that have been sequenced in case and control populations leading to the discovery of rare variants. Some of the variants – even those with clear impact on protein structure and function - have failed replication (Ref. 81). The whole genome and exome projects for schizophrenia will provide a clearer picture of the overall disease risk from rare variants – and reveal the extent of incomplete penetrance.

Transcriptomic studies

In contrast to primary genetic defects, the following three sections concentrate on the assessment of cellular activity and reactivity. Post-mortem gene expression studies have compared gene transcription between brain tissue samples taken from healthy control individuals and those from individuals diagnosed with schizophrenia. Originally, this was undertaken on a hypothesis-driven, gene-by-gene basis: for example, studying glutamate receptor expression changes in the schizophrenic brain (Ref. 82, 83, 84). The availability of full gene-set microarray chips has widened the search to reveal novel diagnostic biomarkers (Ref. 85, 86) as well as the gene ontologies (descriptors of biological function or location) significantly contributing to the pathology and aetiology of disease (Ref. 87).

However, many extraneous factors modify expression profiles including response to drug treatment, age, gender and physiological state of the individual at death, the cell-type complexity of the tissue excised for analysis and the preservation of the tissue post mortem. Additionally, there is uncertainty whether transcriptional changes reflect cause (which itself will be of heterogeneous nature between individuals) or a secondary

response to the disease state. With the adoption of large sample sets and best technical/analytical practice, the results from microarray studies have shown some convergence on particular biological processes. These include metabolic regulation, mitochondrial activity, synaptic function, inhibitory neurotransmission, oligodendrocyte and myelination processes, ubiquitin–proteasome function, chaperone function, and immune response. These are reviewed in detail elsewhere (Ref. 88, 89, 90, 91, 92, 93, 94). Reduced brain expression of *RGS4* (regulator of G-protein signaling 4) is perhaps the most replicated specific transcriptional change in schizophrenia.

The use of tissue samples, such as blood, from living patients is a route to practical biomarker identification. However, this demands that peripheral gene expression profiles reflect those in the brain and, to date, there are conflicting reports on this matter (Ref. 95, 96, 97, 98). Similarly, many studies have examined gene expression changes in genetic or therapeutic models of schizophrenia in cell lines or transgenic mouse models (Ref. 99, 100, 101). These studies tend to yield relatively robust findings and may prove to be a starting point for biological hypotheses that may be confirmed in post mortem tissue.

A new addition to microarray studies is the search for changes in the endogenous microRNA species that bind gene regulatory sequences and are thought to co-ordinate global transcriptional responses. Human post-mortem studies have been recently summarised (Ref. 102, 103) and the findings indicate a number of specific miRNAs associated with schizophrenia that implicate, via shared ontology of their targets, neurodevelopmental and neurotransmitter pathways in disease pathology. A role for perturbed miRNA signalling in schizophrenia is further suggested by the presence of the *DGCR8* gene in the 22q11.2 VCFS deletion region: this gene encodes a component of the miRNA processing complex.

Proteomic studies

The schizophrenic proteome has also been explored for its biomarker potential; again focussing on clinically accessible tissue samples such as blood serum and cerebrospinal fluid (CSF) (Ref. 104, 105). The studies show good consistency and often overlap with existing genetic findings as recently reviewed in detail (Ref. 105). Alterations in the abundance of proteins with roles in metabolic function, particularly glycolysis, (ENO1, ENO2, ALDOC, PGAM1, TPI1, and LDHB) and the cytoskeleton (INA, NEFL, and SEPT3) are particularly frequently observed associated with schizophrenia (Ref. 106,

107, 108, 109, 110). A recent study found that stimulation of peripheral blood mononuclear cells from schizophrenia patients resulted in significant increases in glycolytic enzyme expression in comparison to the same procedure in healthy controls (Ref. 111).

One specific finding merits further discussion. CSF up-regulation of the secreted factor VGF has been shown in cases of schizophrenia and depression, even before therapeutic drug use (Ref. 112, 113). Independently, VGF has been implicated in metabolic control and appears to mediate the anti-depressant actions of exercise via increased hippocampal neurogenesis (Ref. 114, 115, 116, 117). We have recently demonstrated that the *VGF* gene is a target of the NPAS3 transcription factor (Ref. 118).

Metabonomic studies

Perhaps the most recently developed tool applied to schizophrenia is based on the large-scale biochemical analysis of tissue from patients or transgenic mouse models – usually achieved through a combination of chromatography and high-resolution mass spectrometry (Ref. 119). Improvements in resolution mean that several hundred molecular species can be identified, depending on the precise extraction conditions and separation parameters. Biosynthetic pathway flux, redox balance, cellular energy state, neurotransmitter abundance, and membrane composition can all be assessed. Hence, the resulting data are of a different flavour to those described above; providing a snapshot of the homeostatic interactions between genome-directed enzyme expression, disease pathology, and environmental factors. The results of metabonomic studies of schizophrenia have been reviewed previously (Ref. 120, 121) and frequently include disruptions to three biological processes. Firstly, schizophrenia alters brain lipid composition, for example, phosphatidylethanolamine and phosphatidylcholine (omega-6 forms, in particular) – a state that is reversible with antipsychotic use (Ref. 122, 123, 124, 125). This interaction with medication is further indicated by the general and specific changes in lipid pathway transcriptomics induced by a wide spectrum of neuroleptics (Ref. 101). Secondly, schizophrenia, like other CNS disorders such as Parkinson's, Alzheimer's and Multiple Sclerosis, is associated with metabolic changes consistent with an imbalance in redox state and/or oxidative stress (Ref. 126, 127, 128). Notably, the free radical scavenger glutathione appears to be reproducibly decreased (Ref. 129, 130) and mirrored in the observed genomic deletions of Glutathione S-Transferase genes in schizophrenia (Ref. 131). Thirdly, and perhaps closely related to

these defective oxidative processes, are the reported deficiencies in glucose utilisation (Ref. 132) and energy production that point to perturbed anaerobic glycolysis and mitochondrial oxidative respiration (Ref. 133, 134). The role of glucose metabolism is especially relevant in the context of the increased risk of metabolic syndrome/type II diabetes in schizophrenia. While this can often be linked with antipsychotic side-effects, there is good evidence for inherent deficits of glucose metabolism in drug naïve patients (Ref. 135, 136). Oxidative damage to the mitochondrial genome has been frequently reported in schizophrenia, highlighting this organelle as a focus of pathology (Ref. 137). Additionally, mitochondrial morphology and subcellular distribution are known to be regulated by DISC1 and its interactors such as IMMT/mitofilin (Ref. 138, 139, 140). The metabolomic approach may help expand transgenic animal model phenotyping. We recently demonstrated that *Npas3* knockout brain tissue has specific disturbances of the NAD⁺ redox intermediate as well as components of the glucose and pentose phosphate metabolic pathways: a finding that was supported by *in vitro* analysis of this transcription factor's gene targets (Ref. 118).

Established candidate genes

Specific gene-hunting methods have led to the discovery of several strong candidate schizophrenia genes. Three of these are briefly summarised here: *DTNBP1* (dystrobrevin-binding protein 1/dysbindin) (Ref. 141), *NRG1* (neuregulin) (Ref. 142) and *DISC1* (disrupted in schizophrenia) (Ref. 61). Each has spawned a dedicated research field employing cell biology and transgenic mouse modelling to link gene function to disease.

Dysbindin is known to interact with component proteins of the biogenesis of lysosome-related organelles complex 1 (BLOC-1) and dystrophin associated protein complex (DPC) (Ref. 143). A number of directly interacting proteins in these complexes (e.g., CMYA5) have also been independently linked with risk of schizophrenia. Other candidate disease proteins such as NRXN1 and LARGE are indirectly associated with the DPC.

Neuregulin encodes multiple isoforms of a growth factor with known roles in both neuronal (inhibitory interneuron) and glial cell function. NRG1 isoform Type IV has particular relevance to schizophrenia as its promoter lies close to the SNP with strongest genetic association with illness. Neuregulin signals through the ErbB4 receptor that has also been associated with schizophrenia (Ref. 144, 145)

In the ten years since the discovery of *DISC1*, work on the gene has moved from genetic risk confirmation to extrapolation of function by mapping protein interactors (Ref. 60, 146) and, finally, onto pathological and behavioural studies in transgenic mouse models. **Figure 1** summarises the predominant cellular roles of *DISC1* by presenting the multiple protein interactions that have been described at the nucleus, mitochondrion, centrosome, growth cone and synapse. One particularly important *DISC1* function can be summarised as the harnessing of the cytoskeleton for intracellular trafficking, cellular movement and axonal extension which, in turn, contributes to structural brain development and clinical manifestations.

Figure 1 legend here to maintain reference numbering

The function of *DISC1* has been defined by its protein interactions and has generated deep insights into the molecular basis of neurodevelopmental failures central to the aetiology of schizophrenia. *DISC1* (yellow) is shown at two locations in the centre of the diagram and its interactors lead to various outputs located at the top and bottom. In the case of the centrosome, cytoskeleton and axonal growth/migration, all three can be considered different aspects of the same neurodevelopmental pathway. The data (only a subset of the total) have been assembled from general (Ref. 147, 148, 149, 150, 151, 152, 153, 154) and specific protein interaction papers. *DISC1* interacts with *KALRN/HAPIP* (Ref. 155), *DBZ/ZNF365A* (Ref. 147, 148), the *NDE1* complex (Ref. 156, 157), *BBS4* and *PCM1* (Ref. 158), *PDE4B* (Ref. 66), *FEZ1* (Ref. 151), *CAMD1* (Ref. 159), *GIRDIN* and *AKT* (Ref. 160, 161), *KIF5A* and *YHWAE/14-3-3 ε* (Ref. 162, 163, 164), *DIXDC1* (Ref. 165), and *IMMT/mitofilin* (Ref. 140).

Functional paradigms in schizophrenia

Cellular trends

As the schizophrenia risk gene/protein sets accumulate and resolve, they are assessed for statistically significant over-representation of certain ontologies. This convergence of processes and pathways thus defines likely biological causes of schizophrenia. The genomic dissection of autistic spectrum disorders (ASD), accelerated by its substantial cytogenetic component, has led the way in this regard, with at least three clear functional asymptotes discovered – that of the structure and function of the synapse, axonal

insulation, and the mTOR pathway (Ref. 166, 167). In **Figure 2**, a model neuron is shown together with a subset of the genes/proteins detailed within this review grouped according to their typical functions/subcellular locations. Does it permit new insights beyond the banal fact that synapses, axons and dendrites are all important in schizophrenia aetiology? The concentrated cytoskeletal and mitochondrial/metabolic links may be the most revealing aspects. The former is in line with the action of the DISC1 complex detailed above. Thus we can place the cytoskeletal processes of intracellular trafficking as well as the dynamic migration of neurons and axonal extension during developmental at the forefront of aetiological processes linked with schizophrenia. The density of proteins involved in glycolysis and mitochondrial function is an indication of the perturbed state of brain energy regulation in schizophrenia.

In summary, a variety of techniques persuasively suggest that deficiencies of the synapse, cytoskeleton, cell adhesion, metabolism, and oligodendrocyte function are key factors underlying schizophrenia.

The immune system

As studies of schizophrenia transition from the cellular to organism level, several biological processes become apparent including inflammation and adult neurogenesis. Epidemiological data have long supported an immune component to schizophrenia. The increased risk of schizophrenia due to habitation in an urban environment (Ref. 168) may be explained by increased exposure to infectious disease (Ref. 169). The proposed mechanism is via effects of maternal infections during pregnancy impinging on the formation of the foetal brain during critical neurodevelopmental stages. Specific infections, such as the cat-borne *Toxoplasma gondii* parasite, have been repeatedly associated with risk of schizophrenia and linked to behavioural and cognitive performance changes (Ref. 170, 171). At the molecular level, there is evidence for increased levels of inflammatory markers (e.g., interleukins) in the brains of those diagnosed with schizophrenia. Interleukin administration during rodent development can induce schizophrenia-like phenotypes (Ref. 172). Targeting these inflammatory processes in schizophrenia – for example, by reducing prostaglandin E2 production with the non-steroidal anti-inflammatory drug, aspirin (Ref. 173) – appears to be a useful adjunct to conventional antipsychotic treatment.

En masse analysis of GWAS data sets has described a relationship between schizophrenia and bipolar disorder but clearly distances them both from the core group

of common, complex genetic disorders known to share an autoimmune component (e.g., rheumatoid arthritis - RA, Crohn's disease - CD, multiple sclerosis – MS, and types I or II diabetes – T1D/T2D) (Ref. 25). Nevertheless, the association between schizophrenia and the MHC region on chromosome 6 suggests a link may exist. A recent analysis of GWAS overlaps among the autoimmune disorders (Ref. 174) identified genes with considerable relevance to schizophrenia. For example, *NRXN1* (a shared risk factor for RA, CD and MS), *TRIM27* (RA, CD and T1D) - and with less statistical significance for overlap - *ZNF804A* (RA, T1D), *CSMD1* (RA, MS), and *ZDHHC8* (RA, T2D), have also been identified in the schizophrenia GWAS and CNV literature.

Immunostimulation of mice using compounds such as lipopolysaccharide or polyI:C has recently been used in an attempt to model such gene x environment interactions. Both postnatal and *in utero* treatments of polyI:C have been employed in mice over-expressing a dominant-negative mutant form of the human DISC1 protein (Ref. 175, 176, 177). For both time-points, combining immunostimulation and mutant DISC1 over-expression resulted in significantly greater phenotypic consequences than treatment or over-expression alone. The effects were diverse, ranging from increased anxiety/depression, altered social interaction, behavioural paradigm performance changes, memory deficits, altered interleukin production (IL-1 β up, IL-5 down), reduced HPA axis activation in stressful conditions, reduction in DISC1-specific enlargement of lateral ventricles, reduction in parvalbumin-expressing interneuron number, and reduced dendritic spine density. These are important hypothesis-driven experiments that expose the breadth of responses to gene-environment interaction but, as yet, do not fully reveal whether these effects are independent (additive risk) or mechanistically synergistic (a role for DISC1 in immunomodulation). In terms of linking DISC1 to immune response, it is intriguing to note that one of its protein interactors, ZNF365 (DBZ/KIAA0844), is also a key candidate for Crohn's disease (Ref. 178) and breast cancer (Ref. 179), both with immune components to their aetiologies.

Aside from proinflammatory pathways, new interest in the actions of the innate and adaptive immune systems in the central nervous system has been sparked by the realisation of the extent to which both MHC I and complement cascade proteins such as C3 contribute to synapse pruning during development (for example, the visual system in the dorsolateral geniculate nucleus) and in neurodegenerative disorders (Ref. 180). This is particularly intriguing when it is considered that excessive synaptic pruning within the adolescent pre-frontal cortex may directly precede and contribute to the onset of

schizophrenia (Ref. 181, 182, 183). The protein CSMD1, discussed above, appears to play a role in complement pathway regulation.

Adult neurogenesis

Structural brain imaging studies support a neurodevelopmental model of schizophrenia (Ref. 3). This model is physically manifest at the levels of proliferation, differentiation and migration of neurons during the embryonic formation of the cortex and, later, recapitulated as the addition of new granule cells to the dentate gyrus region of the hippocampus in adulthood (Ref. 184, 185). At the molecular level, protein interactors such as DISC1, NDE1 and PAFAH1B1, for example, are known to be vital participants in both the embryonic and adult processes. Moreover, both processes involve a defined layer of stem cells located within the subventricular zone (SVZ) or subgranular zone (SGZ) that generate a neuronal progenitor population dividing to produce daughter cells committed to a neural fate. Importantly, the process doesn't begin and end with this proliferation; in adult neurogenesis, only a proportion of the new neurons successfully differentiate, migrate and integrate permanently into the existing neuronal architecture – the remainder apoptose.

Post-mortem studies showing that adult neurogenesis is attenuated in schizophrenia (Ref. 186) together with evidence that it is improved by antipsychotic treatment have sparked enormous interest in it as a potential pathology that may also reflect defects in embryonic neurodevelopment (Ref. 185). Dentate gyrus granule cells form one of the component synaptic junctions – mossy fibre synapses - in the hippocampal trisynaptic circuitry that contribute to the long-term activity-dependent synaptic plasticity changes (long-term potentiation - LTP) thought to underlie learning and memory. Therefore neurogenesis, via effects on LTP, has the potential to contribute to some of the cognitive aspects of schizophrenia, although evidence to support this is currently incomplete (Ref. 187).

The rate of neurogenesis in transgenic mouse models of schizophrenia (as measured by the incorporation of nucleotide analogues into the genomic DNA of dividing cells) provides an attractive means to quantify effects of the single genetic defect and correlate this with behavioural and cognitive deficits. However, adult neurogenesis does not measure up perfectly as a causative pathology in schizophrenia. Firstly, neurogenesis declines steeply with age in rodents and humans which is at odds with the course of schizophrenia. Secondly, neurogenic proliferation is a highly reactive phenomenon.

Many stimuli seem able to trigger it including hypoxia, aerobic exercise, environmental stimulation, sex hormones, and seizures. Thirdly, it is somewhat disconcerting to see it touted as an important pathology in Alzheimer's (Ref. 188) and other forms of neurodegeneration (Ref. 189, 190, 191, 192). In the light of these conflicting properties, one pragmatic stance might be that levels of adult hippocampal neurogenesis provide a useful barometer of neurodevelopmental competence, general cognitive activity and 'health status' of the brain – rather than a specific risk factor for schizophrenia.

Transgenic mouse models of schizophrenia have been vital in driving the association between neurogenesis and schizophrenia. Multiple strains with *Disc1* dysfunction have comprehensively dissected the gene's role in embryonic and adult neurogenesis revealing participation in both the proliferative and migration/maturation stages (Ref. 160, 161, 193, 194, 195, 196, 197, 198, 199, 200, 201).

Mice lacking the *Npas3* gene also display cognitive, behavioural and neurodevelopmental phenotypes (including adult neurogenesis deficiency) consistent with a model for human psychiatric illness (Ref. 202, 203, 204). A recent paper (Ref. 205) described an *in vivo* screen for small molecules that could reverse the neurogenesis phenotype in *Npas3* mutant mice. One molecule that achieved this, P7C3, helped determine that the *Npas3* neurogenesis failure was due to increased levels of apoptotic death among newly formed neurons, rather than defective proliferation. As electro-convulsive stimulation of *Npas3* knockout mice also restores neurogenesis, it might be speculated that *Npas3* acts as a survival checkpoint: determining whether new neurons are registering 'activity' consistent with appropriate integration into dentate gyrus circuitry. Intriguingly, the *Npas3* knockout deficits appear to be a consequence of mitochondrial fragility – in line with the metabolic defects described earlier – making this gene a point of convergence for glucose metabolism and neurodevelopmental risk mechanisms.

Outstanding issues in schizophrenia biology

The recent progress in the study of schizophrenia is beginning to place the disorder within a robust framework of key biological processes. However, three outstanding issues have emerged, and tackling them may greatly facilitate the practical application of this new-found knowledge.

Personal schizophrenia

There is a need to quantify genetic risk at the level of the individual. GWAS identifies common genetic variants contributing to population risk of psychiatric illness. It can be thought of as utilising a ‘horizontal’ approach in which averaged allele frequencies are compared between cohorts of cases and healthy controls. This is in contrast to ‘vertical’ studies such as CNV detection and exome resequencing which define the genetic status of the individual. The consequence of this distinction is that GWAS variants are not studied in their genomic context – as an additive (or even multiplicative) contribution to an individual’s mutational load. The horizontal approach benefits considerably from statistical power but the vertical approach comes closer to the clinical goal of predictive testing for disease status and effective treatment. With common genetic variation predicted to act via transcriptional regulation, there is now an opportunity to combine genomic and transcriptomic datasets to reveal those ‘expression quantitative trait loci’ (eQTLs) with greatest relevance to schizophrenia aetiology in the individual (Ref. 206, 207, 208, 209, 210). Such studies – already applied to DISC1 pathway biology (Ref. 211), and supported by a very recent proof-of-concept study (Ref. 212) - will require the correlation of CNS-relevant expression profiles from multiple individuals diagnosed with schizophrenia with their genome-wide SNP genotypes. The generation and neuronal differentiation of patient induced pluripotent stem (iPS) cell lines may provide the appropriate material to make this approach feasible (Ref. 213, 214, 215).

Overlapping aetiologies

The estimate of a 50% genetic overlap between schizophrenia and bipolar and its further biological relationships with ASD, epilepsy and mental retardation requires reassessment of both simple models of neuropsychiatric disorder classification and single-process aetiologies. It may also force a categorisation of risk factors according to their mode and site of action. If it is found that much of the shared genetic variation is present in the neurodevelopmental gene fraction then a model based on a ‘fragile brain’ endophenotype might be constructive. Such a model would be consistent with the substantial genetic heterogeneity observed as it would just require an initial generalised deficiency in brain function/connectivity. A secondary hit by other genetic factors or the environment would then produce diagnosis-specific pathologies (**Figure 3**). Applying a crude computer analogy, the neurodevelopmental failures may cause relatively non-

specific defects in hardware while disease-specific processes target specific routines in the software.

Cause and effect in schizophrenia

An important issue is how to define the point of action of any biological process linked with schizophrenia (**Figure 3**). Are we able to distinguish those biological pathways that are *bona fide* primary causes of schizophrenia from those that are the downstream reaction to, or homeostatic consequences of, schizophrenia or environmental risk factors? This may have pertinence for diagnosis and treatment. Genetic or molecular factors identified through the methods outlined above might reflect patient-specific responses to a primary deficit just as much as the primary deficit itself, and so an early-life diagnostic test might be better aimed at the latter. Similarly, therapeutic drugs may be best targeted to the root causes or downstream consequences of disease (or both (Ref. 173)). In such a model, where do current antipsychotics act? As one moves up the biological hierarchy from gene to cell to organ and then individual, reactive processes are likely to be more prevalent (**Figure 3**). The process of inflammatory response would perhaps fall into the reactive category whereas cytoskeleton function, for example, might be considered causative. Embryonic neurogenesis would be causative, adult neurogenesis potentially reactive. This distinction would be mirrored in the discovery arena too. Genomic strategies are likely to reflect cause (although there will clearly be a genetic component to reaction) whereas other ‘-omics’ would be increasingly influenced by environment and disease state. The skewed distribution of evidence for metabolic disturbance in the upper part of the hierarchy, as detailed above, suggests it plays more of a reactive or secondary role – however, the *Npas3* findings argue otherwise. Perhaps the detection of cell autonomous defects, a possible corollary of causation, may be ideally suited to resolve the cause-effect dilemma. Again, the study of patient iPS cells might be invaluable in this regard.

A biological definition of the causes of schizophrenia is now a realistic, albeit challenging, goal. Its potential to influence therapeutic strategies, diagnostic methods and social acceptance of those diagnosed would be considerable: more than justifying the time, effort, cost and frustration involved in its formation.

Acknowledgements

The author wishes to thank the reviewers and editors for their constructive comments and suggestions during the submission process.

Figure legends

Figure 1

The function of DISC1 has been defined by its protein interactions and has generated deep insights into the molecular basis of neurodevelopmental failures central to the aetiology of schizophrenia. DISC1 (yellow) is shown at two locations in the centre of the diagram and its interactors lead to various outputs located at the top and bottom. In the case of the centrosome, cytoskeleton and axonal growth/migration, all three can be considered different aspects of the same neurodevelopmental pathway. The data (only a subset of the total) have been assembled from general (Ref. 147, 148, 149, 150, 151, 152, 153, 154) and specific protein interaction papers. DISC1 interacts with KALRN/HAPIP (Ref. 155), DBZ/ZNF365A (Ref. 147, 148), the NDE1 complex (Ref. 156, 157), BBS4 and PCM1 (Ref. 158), PDE4B (Ref. 66), FEZ1 (Ref. 151), CAMD1 (Ref. 159), GIRDIN and AKT (Ref. 160, 161), KIF5A and YHWAE/14-3-3 ϵ (Ref. 162, 163, 164), DIXDC1 (Ref. 165), and IMMT/mitofilin (Ref. 140).

Figure 2

Convergent locations and actions of genes/proteins implicated in risk of schizophrenia from multiple discovery approaches. Neuron adapted from a Wikimedia Commons image (http://commons.wikimedia.org/wiki/File:Complete_neuron_cell_diagram_en.svg).

Figure 3

Models of schizophrenia biology and analysis. In this speculative representation, distinctions between biological cause and effect are presented from left to right. These highlight primary deficits and reactionary responses in schizophrenia, the specific stages of biological processes that might be involved, the progression from general mental illness susceptibility to specific diagnoses, and the competence of commonly employed investigative techniques to resolve these aspects. 'G X E' indicates the combined effect of genes and environment on risk.

References

- 1 Liddle, P.F. (1987) The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. *Br J Psychiatry* 151, 145-151
- 2 Karam, C.S. et al. (2010) Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. *Trends Pharmacol Sci* 31, 381-390
- 3 Meyer-Lindenberg, A. (2010) From maps to mechanisms through neuroimaging of schizophrenia. *Nature* 468, 194-202
- 4 Segal, D. et al. (2007) Oligodendrocyte pathophysiology: a new view of schizophrenia. *Int J Neuropsychopharmacol* 10, 503-511
- 5 Arnold, S.E. (1999) Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. *Dev Psychopathol* 11, 439-456
- 6 Kety, S.S. (1988) Schizophrenic illness in the families of schizophrenic adoptees: findings from the Danish national sample. *Schizophr Bull* 14, 217-222
- 7 Kendler, K.S. (1983) Overview: a current perspective on twin studies of schizophrenia. *Am J Psychiatry* 140, 1413-1425
- 8 Risch, N. (1990) Genetic linkage and complex diseases, with special reference to psychiatric disorders. *Genet Epidemiol* 7, 3-16; discussion 17-45
- 9 Gottesman, I.I. (1991) Schizophrenia genesis: the origins of madness. (eds), Freeman, New York
- 10 Bodmer, W. and Bonilla, C. (2008) Common and rare variants in multifactorial susceptibility to common diseases. *Nat Genet* 40, 695-701
- 11 Lichtenstein, P. et al. (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 373, 234-239
- 12 Williams, H.J. et al. (2011) Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. *Hum Mol Genet* 20, 387-391
- 13 Craddock, N. and Owen, M.J. (2005) The beginning of the end for the Kraepelinian dichotomy. *Br J Psychiatry* 186, 364-366
- 14 Huang, J. et al. (2010) Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. *Am J Psychiatry* 167, 1254-1263
- 15 Faraone, S.V., Taylor, L. and Tsuang, M.T. (2002) The molecular genetics of schizophrenia: an emerging consensus. *Expert Rev Mol Med* 4, 1-13
- 16 Harrison, P.J. and Weinberger, D.R. (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. *Mol Psychiatry* 10, 40-68
- 17 Ross, C.A. et al. (2006) Neurobiology of schizophrenia. *Neuron* 52, 139-153
- 18 Carter, C.J. (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. *Schizophr Res* 86, 1-14
- 19 Jarskog, L.F., Miyamoto, S. and Lieberman, J.A. (2007) Schizophrenia: new pathological insights and therapies. *Annu Rev Med* 58, 49-61
- 20 Hayashi-Takagi, A. and Sawa, A. (2010) Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. *Brain Res Bull* 83, 140-146
- 21 Bray, N.J. et al. (2010) The neurobiology of schizophrenia: new leads and avenues for treatment. *Curr Opin Neurobiol* 20, 810-815
- 22 Kirov, G. et al. (2009) A genome-wide association study in 574 schizophrenia trios using DNA pooling. *Mol Psychiatry* 14, 796-803

- 23 O'Donovan, M.C. et al. (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. *Nat Genet* 40, 1053-1055
- 24 Lencz, T. et al. (2007) Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. *Mol Psychiatry* 12, 572-580
- 25 Purcell, S.M. et al. (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460, 748-752
- 26 Stefansson, H. et al. (2009) Common variants conferring risk of schizophrenia. *Nature* 460, 744-747
- 27 Shi, J. et al. (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 460, 753-757
- 28 Ikeda, M. et al. (2010) Genome-wide association study of schizophrenia in a Japanese population. *Biol Psychiatry* 69, 472-478
- 29 Athanasiu, L. et al. (2010) Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. *J Psychiatr Res* 44, 748-753
- 30 Chen, X. et al. (2010) GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. *Mol Psychiatry* [Epub]
- 31 Wang, Z. et al. (2006) A review and re-evaluation of an association between the NOTCH4 locus and schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* 141B, 902-906
- 32 Sha, L. et al. (2011) SOX11 target genes: implications for neurogenesis and neuropsychiatric illness. *Acta Neuropsychiatrica* (in press)
- 33 Wang, K., Li, M. and Hakonarson, H. (2010) Analysing biological pathways in genome-wide association studies. *Nat Rev Genet* 11, 843-854
- 34 Jia, P. et al. (2010) Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. *Schizophr Res* 122, 38-42
- 35 O'Dushlaine, C. et al. (2011) Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. *Mol Psychiatry* 16, 286-292
- 36 Redon, R. et al. (2006) Global variation in copy number in the human genome. *Nature* 444, 444-454
- 37 Lee, C. and Scherer, S.W. (2010) The clinical context of copy number variation in the human genome. *Expert Rev Mol Med* 12, e8
- 38 Conrad, D.F. et al. (2010) Origins and functional impact of copy number variation in the human genome. *Nature* 464, 704-712
- 39 Grozeva, D. et al. (2010) Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. *Arch Gen Psychiatry* 67, 318-327
- 40 Tam, G.W. et al. (2009) The role of DNA copy number variation in schizophrenia. *Biol Psychiatry* 66, 1005-1012
- 41 Bassett, A.S., Scherer, S.W. and Brzustowicz, L.M. (2010) Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. *Am J Psychiatry* 167, 899-914
- 42 Sebat, J., Levy, D.L. and McCarthy, S.E. (2009) Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. *Trends Genet* 25, 528-535
- 43 Weiss, L.A. et al. (2008) Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med* 358, 667-675
- 44 Moreno-De-Luca, D. et al. (2010) Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. *Am J Hum Genet* 87, 618-630

- 45 Magri, C. et al. (2010) New copy number variations in schizophrenia. *PLoS One* 5, e13422
- 46 Mulle, J.G. et al. (2010) Microdeletions of 3q29 confer high risk for schizophrenia. *Am J Hum Genet* 87, 229-236
- 47 Karayiorgou, M., Simon, T.J. and Gogos, J.A. (2010) 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. *Nat Rev Neurosci* 11, 402-416
- 48 Ingason, A. et al. (2011) Copy number variations of chromosome 16p13.1 region associated with schizophrenia. *Mol Psychiatry* 16, 17-25
- 49 International Schizophrenia Consortium (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature* 455, 237-241
- 50 Stefansson, H. et al. (2008) Large recurrent microdeletions associated with schizophrenia. *Nature* 455, 232-236
- 51 Walsh, T. et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 320, 539-543
- 52 McCarthy, S.E. et al. (2009) Microduplications of 16p11.2 are associated with schizophrenia. *Nat Genet* 41, 1223-1227
- 53 Levinson, D.F. et al. (2011) Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry* 168, 302-316
- 54 Vacic, V. et al. (2011) Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature* 471, 499-503
- 55 Girirajan, S. et al. (2010) A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. *Nat Genet* 42, 203-209
- 56 Doody, G.A. et al. (1998) 'Pfofschizophrenie' revisited. Schizophrenia in people with mild learning disability. *Br J Psychiatry* 173, 145-153
- 57 Zhang, D. et al. (2009) Singleton deletions throughout the genome increase risk of bipolar disorder. *Mol Psychiatry* 14, 376-380
- 58 Priebe, L. et al. (2011) Genome-wide survey implicates the influence of copy number variants (CNVs) in the development of early-onset bipolar disorder. *Mol Psychiatry* [Epub]
- 59 Muir, W.J., Pickard, B.S. and Blackwood, D.H. (2006) Chromosomal abnormalities and psychosis. *Br J Psychiatry* 188, 501-503
- 60 Chubb, J.E. et al. (2008) The DISC locus in psychiatric illness. *Mol Psychiatry* 13, 36-64
- 61 Millar, J.K. et al. (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. *Hum Mol Genet* 9, 1415-1423
- 62 Muir, W.J., Pickard, B.S. and Blackwood, D.H. (2008) Disrupted-in-Schizophrenia-1. *Curr Psychiatry Rep* 10, 140-147
- 63 St Clair, D. et al. (1990) Association within a family of a balanced autosomal translocation with major mental illness. *Lancet* 336, 13-16
- 64 Gornick, M.C. et al. (2005) Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). *J Autism Dev Disord* 35, 831-838
- 65 Blackwood, D.H. et al. (2001) Schizophrenia and affective disorders-- cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. *Am J Hum Genet* 69, 428-433
- 66 Millar, J.K. et al. (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. *Science* 310, 1187-1191

- 67 Ozeki, Y. et al. (2011) A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression. *Neurosci Res* 69, 154-160
- 68 Pickard, B.S. et al. (2008) A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. *Proc Natl Acad Sci U S A* 105, 14940-14945
- 69 Pickard, B.S. et al. (2006) Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. *Mol Psychiatry* 11, 847-857
- 70 Whalley, H.C. et al. (2009) A GRIK4 variant conferring protection against bipolar disorder modulates hippocampal function. *Mol Psychiatry* 14, 467-468
- 71 Knight, H.M. et al. (2009) A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. *Am J Hum Genet* 85, 833-846
- 72 Kamnasaran, D. et al. (2003) Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. *J Med Genet* 40, 325-332
- 73 Pickard, B.S. et al. (2009) Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. *Mol Psychiatry* 14, 874-884
- 74 Pickard, B.S. et al. (2005) Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability. *Am J Med Genet B Neuropsychiatr Genet* 136B, 26-32
- 75 Ferreira, M.A. et al. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. *Nat Genet* 40, 1056-1058
- 76 Li, Y. et al. (2010) Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. *Nat Genet* 42, 969-972
- 77 Bilguvar, K. et al. (2010) Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations. *Nature* 467, 207-210
- 78 Song, W. et al. (2008) Identification of high risk DISC1 structural variants with a 2% attributable risk for schizophrenia. *Biochem Biophys Res Commun* 367, 700-706
- 79 Tarabeux, J. et al. (2010) De novo truncating mutation in Kinesin 17 associated with schizophrenia. *Biol Psychiatry* 68, 649-656
- 80 Datta, S.R. et al. (2010) A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia. *Mol Psychiatry* 15, 615-628
- 81 Dwyer, S. et al. (2011) Investigation of rare non-synonymous variants at ABCA13 in schizophrenia and bipolar disorder. *Mol Psychiatry* [Epub]
- 82 Porter, R.H., Eastwood, S.L. and Harrison, P.J. (1997) Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. *Brain Res* 751, 217-231
- 83 Sokolov, B.P. (1998) Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. *J Neurochem* 71, 2454-2464
- 84 Meador-Woodruff, J.H., Davis, K.L. and Haroutunian, V. (2001) Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. *Neuropsychopharmacology* 24, 545-552
- 85 Singh, I. and Rose, N. (2009) Biomarkers in psychiatry. *Nature* 460, 202-207

- 86 Schwarz, E. and Bahn, S. (2008) Biomarker discovery in psychiatric disorders. *Electrophoresis* 29, 2884-2890
- 87 Altar, C.A., Vawter, M.P. and Ginsberg, S.D. (2009) Target identification for CNS diseases by transcriptional profiling. *Neuropsychopharmacology* 34, 18-54
- 88 Middleton, F.A. et al. (2002) Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. *J Neurosci* 22, 2718-2729
- 89 Horvath, S., Janka, Z. and Mirnics, K. (2011) Analyzing schizophrenia by DNA microarrays. *Biol Psychiatry* 69, 157-162
- 90 Lewis, D.A. and Mirnics, K. (2006) Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. *Prog Brain Res* 158, 141-152
- 91 Mirnics, K., Levitt, P. and Lewis, D.A. (2006) Critical appraisal of DNA microarrays in psychiatric genomics. *Biol Psychiatry* 60, 163-176
- 92 Iwamoto, K. and Kato, T. (2006) Gene expression profiling in schizophrenia and related mental disorders. *Neuroscientist* 12, 349-361
- 93 Arion, D. et al. (2007) Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. *Biol Psychiatry* 62, 711-721
- 94 Hashimoto, T. et al. (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry* 13, 147-161
- 95 Matigian, N.A. et al. (2008) Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative? *PLoS One* 3, e2412
- 96 Sullivan, P.F., Fan, C. and Perou, C.M. (2006) Evaluating the comparability of gene expression in blood and brain. *Am J Med Genet B Neuropsychiatr Genet* 141B, 261-268
- 97 Takahashi, M. et al. (2010) Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. *Schizophr Res* 119, 210-218
- 98 Middleton, F.A. et al. (2005) Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. *Am J Med Genet B Neuropsychiatr Genet* 136B, 12-25
- 99 Duncan, C.E., Chetcuti, A.F. and Schofield, P.R. (2008) Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. *Psychiatr Genet* 18, 226-239
- 100 Sivagnanasundaram, S. et al. (2007) Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia. *Brain Res* 1139, 48-59
- 101 Polymeropoulos, M.H. et al. (2009) Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. *Schizophr Res* 108, 134-142
- 102 Xu, B., Karayiorgou, M. and Gogos, J.A. (2010) MicroRNAs in psychiatric and neurodevelopmental disorders. *Brain Res* 1338, 78-88
- 103 Forero, D.A. et al. (2010) miRNA genes and the brain: implications for psychiatric disorders. *Hum Mutat* 31, 1195-1204
- 104 Schwarz, E. and Bahn, S. (2008) Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. *Expert Rev Mol Diagn* 8, 209-216
- 105 English, J.A. et al. (2011) The neuroproteomics of schizophrenia. *Biol Psychiatry* 69, 163-172

- 106 Levin, Y. et al. (2010) Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. *Mol Psychiatry* 15, 1088-1100
- 107 Martins-de-Souza, D. et al. (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. *J Psychiatr Res* 44, 1176-1189
- 108 Martins-de-Souza, D. et al. (2009) Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. *BMC Psychiatry* 9, 17
- 109 Johnston-Wilson, N.L. et al. (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. *Mol Psychiatry* 5, 142-149
- 110 English, J.A. et al. (2009) 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. *Proteomics* 9, 3368-3382
- 111 Herberth, M. et al. (2010) Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. *Mol Psychiatry* [Epub]
- 112 Huang, J.T. et al. (2007) CSF metabolic and proteomic profiles in patients prodromal for psychosis. *PLoS One* 2, e756
- 113 Huang, J.T. et al. (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. *PLoS Med* 3, e428
- 114 Malberg, J.E. and Monteggia, L.M. (2008) VGF, a new player in antidepressant action? *Sci Signal* 1, pe19
- 115 Thakker-Varia, S. et al. (2007) The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. *J Neurosci* 27, 12156-12167
- 116 Hunsberger, J.G. et al. (2007) Antidepressant actions of the exercise-regulated gene VGF. *Nat Med* 13, 1476-1482
- 117 Bartolomucci, A. et al. (2007) The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. *Genes Nutr* 2, 169-180
- 118 Sha, L. et al. (2011) Transcriptional regulation of neurodevelopmental and metabolic pathways by NPAS3. *Mol Psychiatry* [Epub]
- 119 Nicholson, J.K. and Lindon, J.C. (2008) Systems biology: Metabonomics. *Nature* 455, 1054-1056
- 120 Quinones, M.P. and Kaddurah-Daouk, R. (2009) Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. *Neurobiol Dis* 35, 165-176
- 121 Kaddurah-Daouk, R. and Krishnan, K.R. (2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. *Neuropsychopharmacology* 34, 173-186
- 122 Kaddurah-Daouk, R. et al. (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. *Mol Psychiatry* 12, 934-945
- 123 Kale, A. et al. (2008) Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. *Schizophr Res* 98, 295-301
- 124 Ross, B.M. (2003) Phospholipid and eicosanoid signaling disturbances in schizophrenia. *Prostaglandins Leukot Essent Fatty Acids* 69, 407-412
- 125 Berger, G.E., Smesny, S. and Amminger, G.P. (2006) Bioactive lipids in schizophrenia. *Int Rev Psychiatry* 18, 85-98
- 126 Do, K.Q. et al. (2009) Redox dysregulation, neurodevelopment, and schizophrenia. *Curr Opin Neurobiol* 19, 220-230
- 127 Yao, J.K. and Keshavan, M.S. (2011) Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View. *Antioxid Redox Signal* [Epub]

- 128 Wang, J.F. et al. (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. *Bipolar Disord* 11, 523-529
- 129 Do, K.Q. et al. (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. *Eur J Neurosci* 12, 3721-3728
- 130 Yao, J.K., Leonard, S. and Reddy, R. (2006) Altered glutathione redox state in schizophrenia. *Dis Markers* 22, 83-93
- 131 Rodriguez-Santiago, B. et al. (2010) Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia. *Mol Psychiatry* 15, 1023-1033
- 132 Holmes, E. et al. (2006) Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. *PLoS Med* 3, e327
- 133 Clay, H.B., Sillivan, S. and Konradi, C. (2011) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. *Int J Dev Neurosci* 29, 311-324
- 134 Scaglia, F. (2010) The role of mitochondrial dysfunction in psychiatric disease. *Dev Disabil Res Rev* 16, 136-143
- 135 Dixon, L. et al. (2000) Prevalence and correlates of diabetes in national schizophrenia samples. *Schizophr Bull* 26, 903-912
- 136 Kohen, D. (2004) Diabetes mellitus and schizophrenia: historical perspective. *Br J Psychiatry Suppl* 47, S64-66
- 137 Rollins, B. et al. (2009) Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. *PLoS One* 4, e4913
- 138 Millar, J.K. et al. (2005) Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria. *Mol Cell Neurosci* 30, 477-484
- 139 James, R. et al. (2004) Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. *Mol Cell Neurosci* 26, 112-122
- 140 Park, Y.U. et al. (2010) Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin. *Proc Natl Acad Sci U S A* 107, 17785-17790
- 141 Straub, R.E. et al. (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. *Am J Hum Genet* 71, 337-348
- 142 Stefansson, H. et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. *Am J Hum Genet* 71, 877-892
- 143 Guo, A.Y. et al. (2009) The dystrobrevin-binding protein 1 gene: features and networks. *Mol Psychiatry* 14, 18-29
- 144 Buonanno, A. (2010) The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. *Brain Res Bull* 83, 122-131
- 145 Banerjee, A. et al. (2010) Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. *Brain Res Bull* 83, 132-139
- 146 Brandon, N.J. et al. (2009) Understanding the role of DISC1 in psychiatric disease and during normal development. *J Neurosci* 29, 12768-12775
- 147 Camargo, L.M. et al. (2007) Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. *Mol Psychiatry* 12, 74-86
- 148 Hattori, T. et al. (2007) A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. *Mol Psychiatry* 12, 398-407

- 149 Millar, J.K., Christie, S. and Porteous, D.J. (2003) Yeast two-hybrid screens implicate DISC1 in brain development and function. *Biochem Biophys Res Commun* 311, 1019-1025
- 150 Miyoshi, K. et al. (2004) DISC1 localizes to the centrosome by binding to kendrin. *Biochem Biophys Res Commun* 317, 1195-1199
- 151 Miyoshi, K. et al. (2003) Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. *Mol Psychiatry* 8, 685-694
- 152 Morris, J.A. et al. (2003) DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. *Hum Mol Genet* 12, 1591-1608
- 153 Ogawa, F., Kasai, M. and Akiyama, T. (2005) A functional link between Disrupted-In-Schizophrenia 1 and the eukaryotic translation initiation factor 3. *Biochem Biophys Res Commun* 338, 771-776
- 154 Ozeki, Y. et al. (2003) Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. *Proc Natl Acad Sci U S A* 100, 289-294
- 155 Hayashi-Takagi, A. et al. (2010) Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. *Nat Neurosci* 13, 327-332
- 156 Hirohashi, Y. et al. (2006) Centrosomal proteins Nde1 and Su48 form a complex regulated by phosphorylation. *Oncogene* 25, 6048-6055
- 157 Wang, Q. et al. (2006) Characterization of Su48, a centrosome protein essential for cell division. *Proc Natl Acad Sci U S A* 103, 6512-6517
- 158 Kamiya, A. et al. (2008) Recruitment of PCM1 to the centrosome by the cooperative action of DISC1 and BBS4: a candidate for psychiatric illnesses. *Arch Gen Psychiatry* 65, 996-1006
- 159 Fukuda, T. et al. (2010) CAMDI, a novel disrupted in schizophrenia 1 (DISC1)-binding protein, is required for radial migration. *J Biol Chem* 285, 40554-40561
- 160 Enomoto, A. et al. (2009) Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. *Neuron* 63, 774-787
- 161 Kim, J.Y. et al. (2009) DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. *Neuron* 63, 761-773
- 162 Bradshaw, N.J. et al. (2008) DISC1, PDE4B, and NDE1 at the centrosome and synapse. *Biochem Biophys Res Commun* 377, 1091-1096
- 163 Brandon, N.J. et al. (2004) Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. *Mol Cell Neurosci* 25, 42-55
- 164 Taya, S. et al. (2007) DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. *J Neurosci* 27, 15-26
- 165 Singh, K.K. et al. (2010) Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. *Neuron* 67, 33-48
- 166 Toro, R. et al. (2010) Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. *Trends Genet* 26, 363-372
- 167 van de Lagemaat, L.N. and Grant, S.G. (2010) Genome variation and complexity in the autism spectrum. *Neuron* 67, 8-10
- 168 Krabbendam, L. and van Os, J. (2005) Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk. *Schizophr Bull* 31, 795-799
- 169 van den Pol, A.N. (2009) Viral infection leading to brain dysfunction: more prevalent than appreciated? *Neuron* 64, 17-20

- 170 Yolken, R.H., Dickerson, F.B. and Fuller Torrey, E. (2009) Toxoplasma and schizophrenia. *Parasite Immunol* 31, 706-715
- 171 Henriquez, S.A. et al. (2009) Neuropsychiatric disease and Toxoplasma gondii infection. *Neuroimmunomodulation* 16, 122-133
- 172 Watanabe, Y., Someya, T. and Nawa, H. (2010) Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. *Psychiatry Clin Neurosci* 64, 217-230
- 173 Laan, W. et al. (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 71, 520-527
- 174 Baranzini, S.E. (2009) The genetics of autoimmune diseases: a networked perspective. *Curr Opin Immunol* 21, 596-605
- 175 Abazyan, B. et al. (2010) Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. *Biol Psychiatry* 68, 1172-1181
- 176 Ayhan, Y. et al. (2011) Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. *Mol Psychiatry* 16, 293-306
- 177 Ibi, D. et al. (2010) Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. *Behav Brain Res* 206, 32-37
- 178 Barrett, J.C. et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 40, 955-962
- 179 Turnbull, C. et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet* 42, 504-507
- 180 Boulanger, L.M. (2009) Immune proteins in brain development and synaptic plasticity. *Neuron* 64, 93-109
- 181 Kolluri, N. et al. (2005) Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. *Am J Psychiatry* 162, 1200-1202
- 182 Sweet, R.A. et al. (2009) Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. *Neuropsychopharmacology* 34, 374-389
- 183 Glantz, L.A. and Lewis, D.A. (2001) Dendritic spine density in schizophrenia and depression. *Arch Gen Psychiatry* 58, 203
- 184 Kempermann, G., Krebs, J. and Fabel, K. (2008) The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. *Curr Opin Psychiatry* 21, 290-295
- 185 Toro, C.T. and Deakin, J.F. (2007) Adult neurogenesis and schizophrenia: a window on abnormal early brain development? *Schizophr Res* 90, 1-14
- 186 Reif, A. et al. (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. *Mol Psychiatry* 11, 514-522
- 187 Deng, W., Aimone, J.B. and Gage, F.H. (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? *Nat Rev Neurosci* 11, 339-350
- 188 Marlatt, M.W. and Lucassen, P.J. (2010) Neurogenesis and Alzheimer's disease: Biology and pathophysiology in mice and men. *Curr Alzheimer Res* 7, 113-125
- 189 Vandenbosch, R. et al. (2009) Adult neurogenesis and the diseased brain. *Curr Med Chem* 16, 652-666
- 190 Kaneko, N. and Sawamoto, K. (2009) Adult neurogenesis and its alteration under pathological conditions. *Neurosci Res* 63, 155-164
- 191 Sailor, K.A., Ming, G.L. and Song, H. (2006) Neurogenesis as a potential therapeutic strategy for neurodegenerative diseases. *Expert Opin Biol Ther* 6, 879-890

- 192 Steiner, B., Wolf, S. and Kempermann, G. (2006) Adult neurogenesis and neurodegenerative disease. *Regen Med* 1, 15-28
- 193 Hikida, T. et al. (2007) Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. *Proc Natl Acad Sci U S A* 104, 14501-14506
- 194 Kvajo, M. et al. (2008) A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. *Proc Natl Acad Sci U S A* 105, 7076-7081
- 195 Pletnikov, M.V. et al. (2008) Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. *Mol Psychiatry* 13, 173-186, 115
- 196 Pletnikov, M.V. et al. (2008) Enlargement of the lateral ventricles in mutant DISC1 transgenic mice. *Mol Psychiatry* 13, 115
- 197 Shen, S. et al. (2008) Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. *J Neurosci* 28, 10893-10904
- 198 Fournier, N.M., Caruncho, H.J. and Kalynchuk, L.E. (2009) Decreased levels of disrupted-in-schizophrenia 1 (DISC1) are associated with expansion of the dentate granule cell layer in normal and kindled rats. *Neurosci Lett* 455, 134-139
- 199 Meyer, K.D. and Morris, J.A. (2009) Disc1 regulates granule cell migration in the developing hippocampus. *Hum Mol Genet* 18, 3286-3297
- 200 Ming, G.L. and Song, H. (2009) DISC1 partners with GSK3beta in neurogenesis. *Cell* 136, 990-992
- 201 Duan, X. et al. (2007) Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. *Cell* 130, 1146-1158
- 202 Pieper, A.A. et al. (2005) The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. *Proc Natl Acad Sci U S A* 102, 14052-14057
- 203 Brunskill, E.W. et al. (2005) Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice. *Eur J Neurosci* 22, 1265-1276
- 204 Erbel-Sieler, C. et al. (2004) Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. *Proc Natl Acad Sci U S A* 101, 13648-13653
- 205 Pieper, A.A. et al. (2010) Discovery of a proneurogenic, neuroprotective chemical. *Cell* 142, 39-51
- 206 Nica, A.C. et al. (2010) Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. *PLoS Genet* 6, e1000895
- 207 Nica, A.C. and Dermitzakis, E.T. (2008) Using gene expression to investigate the genetic basis of complex disorders. *Hum Mol Genet* 17, R129-134
- 208 Geschwind, D.H. and Konopka, G. (2009) Neuroscience in the era of functional genomics and systems biology. *Nature* 461, 908-915
- 209 Veyrieras, J.B. et al. (2008) High-resolution mapping of expression-QTLs yields insight into human gene regulation. *PLoS Genet* 4, e1000214
- 210 Gilad, Y., Rifkin, S.A. and Pritchard, J.K. (2008) Revealing the architecture of gene regulation: the promise of eQTL studies. *Trends Genet* 24, 408-415
- 211 Hennah, W. and Porteous, D. (2009) The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes. *PLoS One* 4, e4906
- 212 Richards, A.L. et al. (2011) Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain. *Mol Psychiatry* [Epub]

213 Chamberlain, S.J., Li, X.J. and Lalande, M. (2008) Induced pluripotent stem (iPS) cells as in vitro models of human neurogenetic disorders. *Neurogenetics* 9, 227-235

214 Brennand, K.J. et al. (2011) Modelling schizophrenia using human induced pluripotent stem cells. *Nature* 473, 221-225

215 Chiang, C.H. et al. (2011) Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. *Mol Psychiatry* 16, 358-360

Further reading

<http://www.schizophreniaforum.org/>

The Schizophrenia Research Forum contains up-to-date news and views on the progress of basic and clinical research into schizophrenia.

<http://www.schizophrenia.com/index.php>

A website much more directed towards informing those diagnosed with schizophrenia together with their families and carers.